title: Coenzyme Q10 for Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.
abstract: BACKGROUND
  Coenzyme Q10 (CoQ10) is an antioxidant that enhances the activity of complex I and II in the Electron Transport Chain. Many preclinical and clinical studies evaluated CoQ10 for neuroprotection against Parkinson's disease (PD). The aim of this study is to synthesize evidence from published randomized controlled trials (RCTs) about the benefit of CoQ10 supplementation for patients with Parkinson's disease.
  
  
  METHODS
  We followed the PRISMA statement guidelines during the preparation of this systematic review and metaanalysis. A computer literature search for (PubMed, EBSCO, Web of science and Ovid Midline) was carried out. We included RCTs comparing CoQ10 with placebo in terms of motor functions and quality of life. Outcomes of total Unified Parkinson's Disease Rating Scale (UPDRS), UPDRS I, UPDRS II, UPDRS III and Schwab and England scores were pooled as standardized mean difference (SMD) between two groups from baseline to the endpoint.
  
  
  RESULTS
  Five RCTs (981 patients) were included in this study. The overall effect did not favor either of the two groups in terms of: total UPDRS score (SMD -0.05, 95%CI [-0.10, 0.15]), UPDRS I (SMD -0.03, 95% CI [-0.23, 0.17]), UPDRS II (SMD -0.10, 95%CI [-0.35, 0.15]), UPDRS III (SMD -0.05, 95%CI [-0.07, 0.17]) or Schwab and England score (SMD 0.08, 95%CI [-0.13, 0.29]).
  
  
  CONCLUSIONS
  CoQ10 supplementation does not slow functional decline nor provide any symptomatic benefit for patients with Parkinson's disease.
authors.affiliation: Faculty of Medicine, Zagazig University, Zagazig, Egypt. ahmed01251@medicine.zu.edu.eg.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Negida
authors.forename: Ahmed
authors.initials: A
authors.lastname: Menshawy
authors.forename: Gehad
authors.initials: G
authors.lastname: El Ashal
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Elfouly
authors.forename: Yasmein
authors.initials: Y
authors.lastname: Hani
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Hegazy
authors.forename: Samar
authors.initials: S
authors.lastname: El Ghonimy
authors.forename: Samar
authors.initials: S
authors.lastname: Fouda
authors.forename: Yomna
authors.initials: Y
authors.lastname: Rashad
mesh_terms: D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism*; D016896:Treatment Outcome; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D014451:Ubiquinone; C024989:coenzyme Q10